The peptide space just changed. We’re here to make sense of it.

In July 2026, the FDA is expected to reclassify 12 peptides from research-only status to legally available therapeutic compounds. It’s one of the most significant shifts in the wellness and longevity space in years — and most people have no idea what it means.

PEPVi exists to change that.

We’re a peptide media and reference site built for people who are just starting to learn. Not for researchers, not for biohackers who already know their stacks — for the person who heard the word “peptide” on a podcast and wants to understand what they actually are, whether they’re safe, and whether they’re worth exploring.

The internet has no shortage of peptide content. Most of it is written by vendors trying to sell you something, or researchers writing for other researchers. We’re trying to be neither.

Every article we publish cites peer-reviewed research where it exists, states plainly when evidence is limited, and is written to be understood by someone with zero background in biochemistry. We think you deserve accurate information without having to decode a PubMed abstract to get it.

Who runs PEPVi

PEPVi was founded by Henry Osterweis, a health and wellness researcher and entrepreneur based in New York. Henry covers emerging therapies, regulatory developments, and consumer health trends. He is not a doctor and PEPVi is not a medical publisher — we’re a media company that takes accuracy seriously.

What we cover

• Peptide science and research — what’s known, what’s preliminary, what’s still unclear
• The regulatory landscape — including the ongoing reclassification and what it means in practice
• Practical guidance for beginners — how to evaluate sources, understand delivery methods, and ask the right questions
• Provider and product reviews — coming soon

Contact

For editorial inquiries, corrections, or partnership questions: [email protected]